Results 11 to 20 of about 8,601 (210)

Chimeric antigen receptor T‐cell therapy as a cure for large B‐cell lymphoma [PDF]

HemaSphere, Volume 10, Issue 11, November 2026.
Abstract Large B‐cell lymphoma (LBCL) is cured in most patients with first‐line chemoimmunotherapy; however, 30%–40% of patients will have relapsed or refractory (R/R) disease. Of these patients, those with refractory or early relapsed LBCL may receive chimeric antigen receptor (CAR) T‐cell therapy as their second‐line treatment if they are eligible ...
Danielle S. Wallace, Yashashree Gupta, Carla Casulo, Wendy Osborne   +3 more
wiley   +2 more sources

Model‐Based Analysis with Mechanistic Insights to CAR‐T‐Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel [PDF]

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1027-1040, October 2026.
Model‐informed drug development is increasingly used to support chimeric antigen receptor (CAR)‐T‐cell therapy programs. However, most population pharmacokinetic (PK) CAR‐T‐cell models available in literature are variations of an empirical piecewise‐linear model, which accurately describes the observed data but lacks a mechanistic foundation.
Anna M. Mc Laughlin, Martin Bergstrand, Ana Ruiz‐Garcia, Simone Filosto, Rhine Shen   +4 more
wiley   +2 more sources

Early Integration of CAR T‐Cell Therapy in Mantle Cell Lymphoma: Expert Opinion in the Era of BTK Inhibitors [PDF]

Hematol Oncol
Hematological Oncology, Volume 44, Issue 6, November 2026.
Carlo Visco, Stefania Bramanti, Paolo Corradini, Enrico Derenzini, Pier Luigi Zinzani   +4 more
wiley   +2 more sources

Baseline Tumor Transcriptional Features and Event-Free Survival After Anti-CD19 CAR T-Cell Therapy with Axicabtagene Ciloleucel in Large B-Cell Lymphoma: An Exploratory Reanalysis of the Randomized ZUMA-7 Trial [PDF]

Medical Sciences
Background/Objectives: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with axicabtagene ciloleucel (axi-cel) improves outcomes in relapsed/refractory large B-cell lymphoma (LBCL), but many patients relapse despite retained CD19 expression.
Jean Silva de Souza Resende, Igor Samesima Giner, Maria Gabriela Custodio de Figueiredo, Mariana Martins Paraízo, Enzo Lalli, Mauro Antônio Alves Castro, Bonald Cavalcante de Figueiredo   +6 more
doaj   +2 more sources

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2 [PDF]

Journal of Hematology & Oncology
Background Treatment with brexucabtagene autoleucel (brexu-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, demonstrated a high objective response rate (93%) and complete response rate (67%) in 60 patients with relapsed ...
Javier Muñoz, Frederick L. Locke, Patrick M. Reagan, Andre Goy, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Ian W. Flinn, David B. Miklos, John M. Pagel, Marie José Kersten, Edouard Forcade, Max S. Topp, Roch Houot, Amer Beitinjaneh, Dan Zheng, Mengru Chang, Wangshu Zhang, Rhine R. Shen, Rita Damico Khalid, Ioana Kloos, Michael L. Wang   +21 more
doaj   +2 more sources

Outcomes of refractory and early‐relapsed large B‐cell lymphoma patients after first‐line treatment in the prospective Real‐world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre‐CAR T era [PDF]

Br J Haematol
British Journal of Haematology, Volume 209, Issue 5, Page 2295-2301, November 2026.
Stéphanie Guidez, Aurélien Belot, Fanny Cherblanc, Bastien Lesné, Sylvain Carras, Catherine Thieblemont, Fontanet Bijou, Cédric Rossi, Luc Mathieu Fornecker, Jehan Dupuis, Krimo Bouabdallah, Ludovic Fouillet, Adrien Chauchet, Benoit Tessoulin, Loic Ysebaert, Alice Pauc, Pascale Cony‐Makhoul, Remy Gressin, Gaelle Laboure, Antoine Bonnet, Sandy Amorim, Christophe Fruchart, Roch Houot, Gian Matteo Pica, Carole Soussain, Sophie Dennetiere, Cécile Leyronnas, Pauline Lionne‐Huyghe, Hervé Ghesquières, Pierre Sesques   +29 more
wiley   +2 more sources

Effectiveness of axicabtagene ciloleucel versus conventional treatments as first-line therapy for high-risk large B-cell lymphoma: an external comparator study [PDF]

BMC Cancer
Background Efficacy of Axicabtagene ciloleucel (Axi-cel) as a frontline regimen for high-risk large B-cell lymphoma (LBCL) has been described in ZUMA-12 single-arm trial, yet there is a paucity of data on head-to-head effectiveness comparison between axi-
Ju Hwan Kim, Sungho Bea, Yeeun Choi, Sang Eun Yoon, Won Seog Kim, Seok Jin Kim, Ju-Young Shin   +6 more
doaj   +2 more sources

Das ZUMA-Informationssystem (ZIS)

, 1997
'In diesem Arbeitsbericht werden der Aufbau, die Inhalte und die Nutzung einer ersten Version des ZUMA-Informationssystems (ZIS) beschrieben: ZIS ist ein elektronisches Handbuch über sozialwissenschaftliche Erhebungsinstrumente aus dem deutschsprachigen Raum.
Glöckner-Rist, Angelika, Bandilla, Wolfgang   +1 more
openaire   +2 more sources

Remarks on pottery production, technology and vessel usage in el-Zuma [PDF]

Polish Archaeology in the Mediterranean, 2017
Continuing excavation in the tumuli field in el-Zuma has yielded an extensive pottery assemblage, adding to the material that has already been published in general reports. New types and variants of vessels have been identified.
Ewa Czyżewska-Zalewska
doaj   +1 more source

Images of a nation in crisis

Communicare, 2022
Political cartoonists have, in recent years, faced victimisation for daring to speak truth to power. In December 2010, South African cartoonist, Jonathan Shapiro (Zapiro) was sued for portraying former President Zuma as a rapist.
Rodwell Makombe
doaj   +1 more source